A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpression.

Trial Details

NCT ID
NCT07361562
Phase
PHASE1
Sponsor
Cogent Biosciences, Inc.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • CGT4255
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • Scottsdale, Arizona, United States|33.50921,-111.89903
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Jacksonville, Florida, United States|30.33218,-81.65565
  • Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

  • Have histologically confirmed diagnosis of:
  • Part A: Locally advanced, metastatic, and/or unresectable solid tumor with documented ERBB2-activating alteration or NRG1 gene fusion in blood and/…
  • Part B: Locally advanced, metastatic, and/or unresectable NSCLC with documented ERBB2 mutation in blood and/or tumor
  • Part C: Locally advanced, metastatic and/or unresectable breast cancer with documented ERBB2 mutation in blood and/or tumor or HER overexpression i…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →